Abstract LBO1-02: Pathologic complete response (pCR) of neoadjuvant therapy with or without atezolizumab in HER2-positive, early high-risk and locally advanced breast cancer: APTneo Michelangelo randomized trial
Year: 2024
Type: conference-abstract
Source: Cancer Research
Authors: Luca Gianni, Elisabetta Munzone, Mauro Mansutti, Giampaolo Bianchini, Yann Izarzuzaga, Elena Rota Caremoli, Luc Dirix, Lucia Del Mastro, Santiago González-Santiago, Andreas Schneeweiss, Jose Ponce, Chiun-Shen Huang, Pauline Wimberger, Sevilay Altintas, Miguel Martín, Nicoleta Antone, Christian F. Singer, Ugo De Giorgi, Ana Godoy Ortiz, Hans-Joachim Lueck, Riccardo Spezia, Angelica Fasolo, Giuseppe Viale, Pinuccia Valagussa
Institutions: Fondazione Michelangelo, European Institute of Oncology, Azienda sanitaria universitaria Friuli Centrale, IRCCS Ospedale San Raffaele, Ospedale Papa Giovanni XXIII, University of Antwerp, GZA Ziekenhuizen Campus Sint-Augustinus, GZA Ziekenhuizen, Ospedale Policlinico San Martino, Hospital San Pedro de Alcántara, German Cancer Research Center, University Hospital Heidelberg, National Center for Tumor Diseases, Hospital General Universitario de Alicante Doctor Balmis, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), National Taiwan University, National Taiwan University Hospital, University Hospital Carl Gustav Carus, Technische Universität Dresden, Antwerp University Hospital, Hospital General Universitario Gregorio Marañón, Institute of Oncology Prof. Dr. Ion Chiricuta, Comprehensive Cancer Center Vienna, Medical University of Vienna, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Cáncer, GEICAM – Spanish Breast Cancer Group, Universidad de Málaga, University of Milan
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4396590752